Zealand Pharma disappoints with diabetes drug in phase III
Crucial phase III trial with biotech firm Zealand Pharma's drug hope dasiglucagon did not live up to the hopes of the company and its investors.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coronavirus vaccines are lucrative business
For subscribers
